



NTDs	Manufacturer	Product Name	MOU Period	Current Donation Commitments
Donations Managed by WHO				
Chagas disease	Bayer AG (Germany)	Nifurtimox (30 mg tablets; 120 mg tablets)	2007–2026 2026–2030	<ul style="list-style-type: none"> Up to a total of 12,500,000 tablets for treatment of patients of all ages Up to a total of 14,000,000 tablets for treatment of patients of all ages
	Chemo Group/Insud Pharma (Mundo Sano)	Benznidazole (100 mg tablets; 12.5 mg tablets)	2020–2023 (extension under discussion)	<ul style="list-style-type: none"> 3,000 tablets (12.5mg)/105,000 tablets (100mg) for treatment of paediatric patients (<19 years of age)
Foodborne trematode infections (fascioliasis and paragonimiasis)	Novartis (Switzerland)	Triclabendazole (250mg tablets)	2016–2030	<ul style="list-style-type: none"> Up to 600,000 tablets for the treatment of fascioliasis and paragonimiasis
Foodborne trematode infections (clonorchiasis and opisthorchiasis)	Bayer AG (Germany)	Praziquantel (600 mg tablets)	2020–2030	<ul style="list-style-type: none"> Within the limits of the donation of praziquantel for taeniasis/cysticercosis Bayer AG provides WHO with financial support for limited procurement of praziquantel after stopping this product donation end of 2025.
	Bayer AG (Germany)	Nifurtimox (120 mg tablets)	2009–2026	<ul style="list-style-type: none"> Up to 150,000 tablets for five years, adjustable to needs

NTDs	Manufacturer	Product Name	MOU Period	Current Donation Commitments
Human African trypanosomiasis (HAT)			2026–2030	<ul style="list-style-type: none"> Up to 110,000 tablets for five years, adjustable to needs
		Suramin (1 g in vial)	2002–2026 2026–2030	<ul style="list-style-type: none"> Up to 10,000 vials for five years, adjustable to needs Up to 1,000 vials for five years, adjustable to needs
Human African trypanosomiasis (HAT)	Sanofi (France)	<ul style="list-style-type: none"> Eflornithine (200 mg per mL in 100 mL bottle); Melarsoprol (3.6% in 5 mL ampoule solution (180 mg of active compound); Pentamidine (200 mg powder for injection) 	2001–2026	<ul style="list-style-type: none"> Unlimited quantity for the treatment of human African trypanosomiasis
		<ul style="list-style-type: none"> Fexinidazole (600 mg tablets) 	2019–2026	
	Cytiva (Sweden)	Diagnostics of HAT. DE52 Cellulose (10kg pack size) and Cytopore 2 (1kg pack size)	2022–2024	<ul style="list-style-type: none"> Donation of 15,000 tablets expected in July 2026 for the treatment of the gambiense form of HAT 230 kilograms of DE52 Cellulose, and 9 kilograms of Cytopore 2 enough to cover the need until 2025
			2026–2028 (to be confirmed)	<ul style="list-style-type: none"> 230 kilograms of DE52 Cellulose, and 9 kilograms of Cytopore 2 enough to cover the need until 2030
Leprosy	Novartis (Switzerland)	Clofazimine (100mg capsule)	2000–2030	<ul style="list-style-type: none"> For the treatment of severe erythema nodosum leprosum reactions; quantities will be determined on the basis on annual forecasts and production capacity Under the current MoU (2026–2030), up to 3 million blisters annually for the treatment of leprosy and its complications
		Clofazimine (50mg capsule)		
		MDT ¹ MB Adult & Child MDT PB Adult & Child		
		Rifampicin (150mg, 300mg, syrup)	2024–2030	<ul style="list-style-type: none"> Funding procurement of single dose Rifampicin for Leprosy Chemoprophylaxis (SDR-LEP) for contacts of active leprosy patients
Lymphatic filariasis (LF)	Eisai (Japan)	Diethylcarbamazine citrate (100 mg tablets)	Since 2012 until elimination of LF	<ul style="list-style-type: none"> Up to 2.2 billion tablets committed for first 7-year period for use in the preventive chemotherapy of lymphatic filariasis Extended in 2017 until elimination is achieved

¹ *MDT, multidrug therapy (rifampicin (150mg & 300mg tablets), clofazimine (300 mg & 50mg tablets), dapsone (100mg tablets)) in blister packs depending on age and type of leprosy; loose clofazimine in capsules.

NTDs	Manufacturer	Product Name	MOU Period	Current Donation Commitments
				<ul style="list-style-type: none"> Current MoU valid through 2030
	GlaxoSmithKline (GSK) (United Kingdom)	Albendazole (400mg tablets)	Since 1997 until elimination of LF	<ul style="list-style-type: none"> Up to 600 million tablets annually for use in the preventive chemotherapy of lymphatic filariasis Under current MoU (2026–2030) quantity has been reduced to 500 million tablets
Schistosomiasis	Merck KGaA (Germany)	Praziquantel (600 mg tablets)	Since 2007 for an unlimited period	<ul style="list-style-type: none"> Up to 200 million tablets annually for the treatment of schistosomiasis in school-age children (notably in Africa) Since 2017, donation scaled up to 250 million tablets annually for the treatment of schistosomiasis in school-age children and adults (in specific epidemiological context)
Soil-transmitted helminthiasis (STH)	GlaxoSmithKline (GSK) (United Kingdom)	Albendazole (400mg tablets)	2012–2030	<ul style="list-style-type: none"> Up to 200 million tablets annually for use in the preventive chemotherapy of soil-transmitted helminthiasis
Soil-transmitted helminthiasis (STH)	Janssen Pharmaceuticals, Inc. (United States of America)	Mebendazole (500 mg tablets)	2012–2030	<ul style="list-style-type: none"> Up to 200 million tablets annually for the treatment of soil-transmitted helminthiasis in school-age children and women of reproductive age group.
Visceral leishmaniasis (VL)	Gilead Sciences, Inc. (United States of America)	Liposomal Amphotericin B (lyophilized 50 mg formulation in vials) (AmBisome®)	2012–2016	<ul style="list-style-type: none"> Up to 445,000 vials for the treatment of visceral leishmaniasis in South-East Asia and East Africa
			2016–2021	<ul style="list-style-type: none"> Up to 380,400 vials for the treatment of visceral leishmaniasis in South-East Asia and East Africa
			2022–2025	<ul style="list-style-type: none"> Up to 304 700 vials for the treatment of visceral leishmaniasis in South-East Asia and East Africa
			2026–2030 (to be confirmed)	<ul style="list-style-type: none"> Up to 402 941 vials for visceral leishmaniasis high-burden countries, mainly in South-East Asia and East Africa
Yaws	EMS SA Pharma (Brazil)	Azithromycin (500 mg tablets)	2019–2024	<ul style="list-style-type: none"> 153 million tablets to support the global eradication of yaws.
			2025–2030	<ul style="list-style-type: none"> 143 million tablets to support the global eradication of yaws.
Taeniasis/ cysticercosis	Bayer AG (Germany)	Niclosamide (400 mg tablets)	2020–2024 2025–2030	<ul style="list-style-type: none"> Up to a total of 2,800,000 tablets Up to a total of 4,500,000 tablets
		Praziquantel (600 mg tablets)	2020–2024	<ul style="list-style-type: none"> Up to a total of 1,339,000 tablets Terminated in 2025

NTDs	Manufacturer	Product Name	MOU Period	Current Donation Commitments
Cystic echinococcosis	GlaxoSmithKline (GSK) (United Kingdom)	Albendazole (400mg tablets)	2022–2030	<ul style="list-style-type: none"> Up to 5 million as long as it is within the limit of the overall donation of ALB from GSK
Donations Managed Outside WHO				
Onchocerciasis	Merck, Sharpe and Dome (MSD) (United States of America)	Ivermectin (3 mg tablets)	Since 1987 until elimination of onchocerciasis	<ul style="list-style-type: none"> Unlimited supply for the treatment of onchocerciasis
Lymphatic filariasis (LF)			Since 1997 until elimination of LF	<ul style="list-style-type: none"> Unlimited supply for the treatment of lymphatic filariasis
			2018–2030 for IDA strategy	<ul style="list-style-type: none"> Up to 250 million tablets per year for use in WHO-recommended triple-therapy (IDA) MDA regimen to eliminate LF in countries not co-endemic for onchocerciasis
Trachoma	Pfizer Inc. (United States of America)	Azithromycin (250 mg tablets or 1200 mg in 30 mL (200 mg/5 mL) powder for oral suspension)	1998–2030	<ul style="list-style-type: none"> Unlimited quantity for the elimination of trachoma as a public health problem